The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 1.84
Ask: 1.96
Change: -0.14 (-6.86%)
Spread: 0.12 (6.522%)
Open: 2.00
High: 2.01
Low: 2.00
Prev. Close: 2.04
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Driver records loss; Synectics sells business unit

Fri, 11th Nov 2022 19:56

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Synectics PLC - Sheffield, England-based security systems company - Agrees the conditional sale of its SSS Management Services Ltd business for a cash consideration of up to GBP200,000 to Parfas Ltd. It is a trading entity of its Synectics Security division. Expects the sale to be completed on or before the end of its financial year on November 30. "SSS Management Services is a unique business with a very strong management team that will thrive under private ownership," CEO Paul Webb comments.

----------

Driver Group PLC - Lancashire-based professional services consultancy to construction and engineering industries - Confirms that it expects to report an underlying pretax loss of GBP300,000 for the year which ended September 30 2022. This is before one-off Middle East reorganisation costs of GBP600,000 "due to the Middle East and APAC issues". Plans to scale costs back further. Explains that this will account for the lower revenue it expects as a result of the Middle East and Asia-Pacific reorganisation. Net cash stands at GBP4.8 million as of September 30, 2022. "This has been a particularly challenging year for the business. We have faced head on the legacy challenges in the Middle East and APAC that have damaged the group's overall performance in recent years, masking the excellent contribution made by our business units in the UK, Europe and Americas. We have dramatically reduced our exposure to risk in the Middle East & APAC, which will now make a positive contribution to the group," CEO Mark Wheeler says.

----------

AQRU PLC - London-based incubator for decentralised finance businesses - Partners with managing partners of the UK-based chartered accountancy firm Sampson Fielding Ltd, Ben Sampson and Elliot Fielding. Plans to launch a start-up under the brand "Daxiom" offering technology-led accountancy and advisory services with them. "An increasing number of organisations are entering crypto and DeFi sector but, in doing so, they've found that accounting and reporting their digital assets can be a challenging process, and this constraint on being able to properly report on their assets further undermines investor confidence. By using AQRU's software to quantify and verify the value of digital assets, and Ben Sampson and Elliot Fielding's sector expertise, we're making accounting and reporting easier and taking much of the burden off organisations holding digital assets," CEO Philip Blows comments.

----------

ImmuPharma PLC - specialist drug discovery and development company - Says the Lupuzor for Lupus clinical programme will be redesigned on key protocols. Says that there is a potential for product sales revenue for ImmuPharma by introducing certain Avion Pharmaceuticals LLC, its US partner for Lupuzor, drugs into the European market. Notes that Avion confirmed its continued support to the Lupuzor clinical programme. "We have had extremely positive discussions with Avion over the last month and, following receipt of the written response from the FDA, we have agreed to redesign the clinical program for Lupuzor to encompass the recommendations from the FDA, with a view to enhancing the probability of success. In addition, our discussions have developed the potential of a much broader collaboration whereby we would be working in partnership to introduce certain Avion products into the European market," ImmuPharma CEO Tim McCarthy comments.

----------

Synergia Energy Ltd - Perth-based developer of natural gas assets in India, Indonesia and the UK, formerly called Oilex Ltd - Says the C-77H well at its Cambay operations in India continues to produce on a consistent plateau with gas rates between 255,000 and 275,000 cubic feet per day. Engages Wellynx to design an artificial lift solution for the C-77H well. Expects that the cost will fall within the existing budget.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company focused on copper across Australia and Zambia - Says the Australian Securities Exchange halted trading in its shares from November 11. Explains that it requested the halt pending the release of and announcement of geological results at the Broken Hill project. Anticipates that the trading halt will remain in place until November 15.

----------

Chaarat Gold Holdings Ltd - Armenia and Kyrgyzstan-focused gold mining company - Gets the mineral resource estimate for its Kapan polymetallic mine in Armenia. Estimates 722,000 gold equivalent ounces in the Measured & Indicated categories. This compares to 584,000 oz reported in June 2021, reflecting a 25% increase in MRE. "New drilling converted mineralization to M&I to replace depletion during the period, and the improvements to the mining methods employed at Kapan have enabled an increase to the resource," CEO Michael Fraser explains.

----------

SLF Realisation Fund Ltd - realising all remaining assets in portfolio of ordinary share class and 2016 C share class - Plans to return 1.5 pence per share to shareholders, being GBP5.3 million, based on the current number of shares in issue.

----------

Intelligent Ultrasound Group PLC - Cardiff, Wales-based artificial intelligence ultrasound software firm - Raises GBP5.2 million through the conditional issue of 42.5 million placing shares and 13.7 million subscription shares to new and existing institutional and other investors at a price of 9.25 pence per share. The placing and subscription represent 17% of the enlarged share capital. Plans to use the net proceeds of 4.8 million to strengthen the balance sheet and provide additional working capital.

----------

Woodbois Ltd - London-headquartered African-focused timber producer - Receives a request by the same shareholder for the conversion, on a one-to-one basis, of its remaining 55.0 million non-voting shares into voting shares. The conversion will be effective on admission. Following admission, ordinary shares in issue will remain at 2.49 billion and this will consist of 2.25 billion voting shares and 235.0 million non-voting shares.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Apr 2024 12:52

Immupharma jumps amid new IP strategy for P140 technology platform

(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.

Read more
25 Mar 2024 12:20

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 10:55

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
6 Mar 2024 13:05

EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up

(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Dec 2023 17:52

EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Dec 2023 12:18

IN BRIEF: Incanthera signs skincare stocking deal, raises GBP1 million

Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise.

Read more
7 Sep 2023 17:07

TRADING UPDATES: RA International loss narrows as revenue grows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
31 Aug 2023 13:05

ImmuPharma launches GBP2 million fund raise as interim loss narrows

(Alliance News) - ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under GBP2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses.

Read more
21 Aug 2023 12:33

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

(Alliance News) - Incanthera PLC and ImmuPharma PLC on Monday agreed a 12 month extension to their warrant instrument.

Read more
23 Jun 2023 15:51

UK shareholder meetings calendar - next 7 days

Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
Thursday 29 June 
3i Group PLCAGM
Africa Opportunity Fund LtdAGM
Anemoi International LtdAGM
Anpario PLCAGM
Ariana Resources PLCAGM
Beowulf Mining PLCAGM
Celadon Pharmaceuticals PLCAGM
Cornish Metals IncAGM
East Imperial PLCAGM
East Star Resources PLCAGM
Eden Research PLCAGM
Engage XR Holdings PLCAGM
First Class Metals PLCAGM
Gresham House Energy Storage Fund PLCGM re remuneration policy
Gusbourne PLCAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Ingenta PLCAGM
IQE PLCAGM
Kooth PLCAGM
Landore Resources LtdAGM
Let's Explore Group PLCAGM
Likewise Group PLCAGM
MGC Pharmaceuticals LtdGM re issue of convertible notes
Morgan Advanced Materials PLCAGM
NetScientific PLCAGM
New Century AIM VCT 2AGM
Norman Broadbent PLCAGM
Reabold Resources PLCAGM
Rockhopper Exploration PLCAGM
Roquefort Therapeutics PLCAGM
Serica Energy PLCAGM
SpaceandPeople PLCAGM
Symphony Environmental Technologies PLCAGM
Synairgen PLCAGM
Thalassa Holdings LtdAGM
tinyBuild IncAGM
Touchstone Exploration IncAGM
Trident Royalties PLCAGM
Unigel Group PLCAGM
Verici Dx PLCAGM
Xpediator PLCAGM
Friday 30 June 
Argo Blockchain PLCAGM
Ascent Resources PLCAGM
Bluejay Mining PLCAGM
Caspian Sunrise PLCAGM
Codex Acquisitions PLCAGM
Domino's Pizza Group PLCGM re directors' remuneration policy
Fenikso LtdAGM
Fiinu PLCAGM
FireAngel Safety Technology Group PLCAGM
GENinCode PLCAGM
Hemogenyx Pharmaceuticals PLCAGM
Hiro Metaverse Acquisitions I SAAGM
i3 Energy PLCGM re premium share cancellation
ImmuPharma PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kefi Gold & Copper PLCAGM
Kistos Holdings PLCAGM
KRM22 PLCAGM
Kropz PLCAGM
LoopUp Group PLCAGM
Medica Group PLCAGM
Mirriad Advertising PLCAGM
Rockfire Resources PLCAGM
Savannah Energy PLCAGM
Strip Tinning Holdings PLCAGM
ThomasLloyd Energy Impact Trust PLCAGM
URA Holdings PLCAGM
World Chess PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jun 2023 12:02

IN BRIEF: ImmuPharma to start next two phases of Lupuzor trial

ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food & Drug Administration. Says the clinical trial will be supported by Avion Pharmaceuticals. Adds further details of the trial will be shared at a later stage. Lupuzor, or P140, is a potential treatment for Lupus disease.

Read more
18 May 2023 12:12

IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus.

Read more
11 May 2023 11:48

IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market."

Read more
19 Apr 2023 15:40

IN BRIEF: ImmuPharma says US FDA confirms date for Lupuzor meeting

ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.